GlassScriptPhysician profile
Diane Menier
NPI 1104089705
$7,054.34
in general payments reported to CMS, 2019-2025
47 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $645 · 2022: $1,252 · 2023: $1,786 · 2024: $1,065 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257 · Education: $814 · Honoraria: $788 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.09 |
| Education | $814.10 |
| Honoraria | $787.50 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,394.58 | 2021-2025 | |
| Janssen Biotech, INC. | $885.50 | 2021-2025 | Rybrevant, Tecvayli, Erleada |
| Pharmaessentia USA Corporation | $812.11 | 2024-2025 | Besremi |
| Astellas Pharma US INC | $529.71 | 2021-2025 | Padcev, Xospata |
| Stemline Therapeutics INC. | $399.02 | 2023-2025 | Orserdu |
| Incyte Corporation | $274.94 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Gilead Sciences, INC. | $227.96 | 2022-2024 | Trodelvy |
| Adaptive Biotechnologies Corporation | $200.08 | 2022-2023 | Clonoseq |
| Abbvie INC. | $173.52 | 2023-2025 | |
| Lilly USA, LLC | $150.28 | 2021-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $146.23 | 2021-2024 | Iclusig |
| Merck Sharp & Dohme LLC | $142.62 | 2021-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $124.82 | 2022 | |
| Glaxosmithkline, LLC. | $118.20 | 2021-2025 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $89.45 | 2021-2025 | Ultomiris |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.95 | 2023 | |
| Amgen INC. | $83.48 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Genzyme Corporation | $82.74 | 2023-2025 | |
| Daiichi Sankyo INC. | $75.66 | 2021-2025 | Enhertu |
| Pfizer INC. | $71.30 | 2021-2022 | |
| Seagen INC. | $70.58 | 2021-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $69.26 | 2021-2023 | Enhertu |
| Puma Biotechnology, INC. | $68.00 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.92 | 2022-2025 | |
| Emd Serono, INC. | $62.97 | 2023-2025 | Mavenclad |
| Regeneron Healthcare Solutions, INC. | $52.23 | 2021-2022 | |
| Genentech USA, INC. | $50.15 | 2025 | Itovebi, Venclexta |
| Eisai INC. | $48.26 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $39.36 | 2022-2023 | |
| Coherus Oncology, INC. | $38.20 | 2023-2024 | |
| Tolmar, INC. | $37.65 | 2024-2025 | Eligard |
| Array Biopharma INC | $33.62 | 2022-2023 | Paxlovid, Mektovi, Comirnaty |
| Genmab U.S., INC. | $32.01 | 2023 | Tivdak |
| Karyopharm Therapeutics INC. | $31.49 | 2022 | |
| Myovant Sciences INC. | $28.85 | 2021 | |
| Kyowa Kirin, INC. | $28.33 | 2021 | |
| Recordati_rare_diseases_inc. | $28.10 | 2025 | Enjaymo |
| Rigel Pharmaceuticals, INC. | $24.50 | 2024 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $23.20 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $22.20 | 2024 | Cosela |
| Lundbeck LLC | $22.12 | 2025 | Vyepti |
| Blueprint Medicines Corporation | $22.05 | 2022 | |
| Tersera Therapeutics LLC | $19.32 | 2025 | Zoladex |
| Taiho Oncology, INC. | $19.25 | 2024 | |
| Sobi, INC | $18.22 | 2025 | |
| Beigene USA, INC. | $15.56 | 2024 | Brukinsa |
| Mirati Therapeutics, INC. | $14.79 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Menier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.